In addition, evidence from studies in cancer cell lines and in mouse models supported the capability of NRF2 to enhance drug resistance against a diverse range of drugs, such as cisplatin, doxorubicin, 5-fluorouracil, paclitaxel, and etoposide [47,48,49,50]. The gene discussed is NFE2L2; the disease is cancer.